O	0	10	Randomized
O	11	19	clinical
O	20	25	trial
O	26	28	of
B-intervention	29	36	Chinese
I-intervention	37	43	herbal
I-intervention	44	55	medications
O	56	58	to
O	59	65	reduce
B-condition	66	71	wound
I-condition	72	85	complications
O	86	91	after
O	92	102	mastectomy
O	103	106	for
O	107	113	breast
O	114	123	carcinoma
O	123	124	.

O	125	134	Ischaemia
O	135	138	and
O	139	147	necrosis
O	148	150	of
O	151	155	skin
O	156	161	flaps
O	162	164	is
O	165	166	a
O	167	173	common
O	174	186	complication
O	187	192	after
O	193	203	mastectomy
O	203	204	.

O	205	209	This
O	210	215	study
O	216	225	evaluated
O	226	229	the
O	230	239	influence
O	240	242	of
B-intervention	243	254	anisodamine
I-intervention	255	258	and
I-intervention	259	265	Salvia
I-intervention	266	278	miltiorrhiza
O	279	281	on
O	282	287	wound
O	288	301	complications
O	302	307	after
O	308	318	mastectomy
O	319	322	for
O	323	329	breast
O	330	336	cancer
O	336	337	.

B-total-participants	338	344	Ninety
B-eligibility	345	353	patients
I-eligibility	354	364	undergoing
I-eligibility	365	375	mastectomy
I-eligibility	376	379	for
I-eligibility	380	386	breast
I-eligibility	387	396	carcinoma
O	397	401	were
O	402	409	divided
O	410	414	into
O	415	420	three
O	421	427	groups
O	427	428	.

O	429	434	Group
O	435	436	1
O	437	445	received
B-control	446	453	routine
I-control	454	459	wound
I-control	460	464	care
O	464	465	,
O	466	471	group
O	472	473	2
O	474	482	received
O	483	494	intravenous
O	495	501	Salvia
O	502	514	miltiorrhiza
O	515	520	after
O	521	528	surgery
O	529	532	for
O	533	534	3
O	535	539	days
O	540	543	and
O	544	549	group
O	550	551	3
O	552	561	similarly
O	562	570	received
O	571	582	intravenous
O	583	594	anisodamine
O	594	595	.

O	596	600	Skin
O	601	606	flaps
O	607	611	were
O	612	620	observed
O	621	623	on
O	624	637	postoperative
O	638	642	days
O	643	644	4
O	645	648	and
O	649	650	8
O	650	651	;
O	652	657	areas
O	658	660	of
O	661	666	wound
O	667	676	ischaemia
O	677	680	and
O	681	689	necrosis
O	690	694	were
O	695	701	graded
O	702	705	and
O	706	713	adverse
O	714	720	events
O	721	729	recorded
O	729	730	.

O	731	736	There
O	737	740	was
O	741	743	no
O	744	754	difference
O	755	757	in
O	758	769	demographic
O	770	785	characteristics
O	786	793	between
O	794	797	the
O	798	804	groups
O	804	805	.

O	806	808	At
O	809	810	4
O	811	815	days
O	816	821	after
O	822	829	surgery
O	830	833	the
B-outcome	834	838	rate
I-outcome	839	841	of
I-outcome	842	851	ischaemia
I-outcome	852	855	and
I-outcome	856	864	necrosis
O	865	867	in
O	868	874	groups
O	875	876	2
O	877	880	and
O	881	882	3
O	883	886	was
O	887	900	significantly
O	901	908	reduced
O	909	917	compared
O	918	922	with
O	923	927	that
O	928	930	in
O	931	938	control
O	939	944	group
O	945	946	1
O	947	948	(
B-outcome	948	954	median
I-outcome	955	960	wound
I-outcome	961	966	score
B-iv-cont-median	967	968	6
I-iv-cont-median	968	969	·
I-iv-cont-median	969	971	80
O	972	978	versus
B-cv-cont-median	979	981	23
I-cv-cont-median	981	982	·
I-cv-cont-median	982	984	38
O	984	985	,
O	986	987	P
O	988	989	=
O	990	991	0
O	991	992	·
O	992	995	002
O	995	996	,
O	997	1000	and
B-iv-cont-median	1001	1002	3
I-iv-cont-median	1002	1003	·
I-iv-cont-median	1003	1005	76
O	1006	1012	versus
B-cv-cont-median	1013	1015	23
I-cv-cont-median	1015	1016	·
I-cv-cont-median	1016	1018	38
O	1018	1019	,
O	1020	1021	P
O	1022	1023	<
O	1024	1025	0
O	1025	1026	·
O	1026	1029	001
O	1029	1030	,
O	1031	1043	respectively
O	1043	1044	)
O	1044	1045	.

O	1046	1050	This
O	1051	1062	improvement
O	1063	1065	in
O	1066	1072	groups
O	1073	1074	2
O	1075	1078	and
O	1079	1080	3
O	1081	1090	continued
O	1091	1093	to
B-outcome	1094	1107	postoperative
I-outcome	1108	1111	day
I-outcome	1112	1113	8
O	1114	1115	(
O	1115	1119	both
O	1120	1121	P
O	1122	1123	<
O	1124	1125	0
O	1125	1126	·
O	1126	1129	001
O	1129	1130	)
O	1130	1131	,
O	1132	1135	but
B-outcome	1136	1141	wound
I-outcome	1142	1148	scores
O	1149	1151	at
O	1152	1156	this
O	1157	1162	stage
O	1163	1167	were
O	1168	1174	better
O	1175	1177	in
O	1178	1183	group
O	1184	1185	3
O	1186	1190	than
O	1191	1193	in
O	1194	1199	group
O	1200	1201	2
O	1202	1203	(
B-iv-cont-median	1203	1204	1
I-iv-cont-median	1204	1205	·
I-iv-cont-median	1205	1207	82
O	1208	1214	versus
B-iv-cont-median	1215	1216	6
I-iv-cont-median	1216	1217	·
I-iv-cont-median	1217	1219	92
O	1220	1232	respectively
O	1232	1233	;
O	1234	1235	P
O	1236	1237	=
O	1238	1239	0
O	1239	1240	·
O	1240	1243	022
O	1243	1244	)
O	1244	1245	.

O	1246	1249	The
B-outcome	1250	1256	volume
I-outcome	1257	1259	of
I-outcome	1260	1265	wound
I-outcome	1266	1274	drainage
O	1275	1278	was
O	1279	1284	lower
O	1285	1287	in
O	1288	1293	group
O	1294	1295	3
O	1296	1300	than
O	1301	1303	in
O	1304	1309	group
O	1310	1311	1
O	1312	1313	(
O	1313	1314	P
O	1315	1316	=
O	1317	1318	0
O	1318	1319	·
O	1319	1322	004
O	1322	1323	)
O	1323	1324	.

O	1325	1328	The
B-outcome	1329	1338	incidence
I-outcome	1339	1341	of
I-outcome	1342	1349	adverse
I-outcome	1350	1357	effects
O	1358	1361	was
O	1362	1369	highest
O	1370	1372	in
O	1373	1378	group
O	1379	1380	3
O	1380	1381	,
O	1382	1385	and
O	1386	1389	two
O	1390	1398	patients
O	1399	1401	in
O	1402	1406	this
O	1407	1412	group
O	1413	1425	discontinued
O	1426	1435	treatment
O	1435	1436	.

O	1437	1439	No
O	1440	1451	significant
B-outcome	1452	1465	complications
O	1466	1470	were
O	1471	1476	noted
O	1477	1479	in
O	1480	1485	group
O	1486	1487	2
O	1487	1488	.

O	1489	1500	Anisodamine
O	1501	1504	and
O	1505	1506	S
O	1506	1507	.
O	1508	1520	miltiorrhiza
O	1521	1525	were
O	1526	1530	both
O	1531	1540	effective
O	1541	1543	in
O	1544	1552	reducing
O	1553	1557	skin
O	1558	1562	flap
O	1563	1572	ischaemia
O	1573	1576	and
O	1577	1585	necrosis
O	1586	1591	after
O	1592	1602	mastectomy
O	1602	1603	,
O	1604	1612	although
O	1613	1624	anisodamine
O	1625	1628	was
O	1629	1639	associated
O	1640	1644	with
O	1645	1646	a
O	1647	1653	higher
O	1654	1658	rate
O	1659	1661	of
O	1662	1669	adverse
O	1670	1677	effects
O	1677	1678	.
